Genevoyager
Wuhan, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Chinese CRO/CDMO specializing in viral vector and vaccine services with proprietary One-Bac 4.0 AAV manufacturing platform.
OncologyInfectious DiseaseNeurologyHepatologyCardiovascular
Technology Platform
One-Bac 4.0 insect baculovirus system for high-yield AAV manufacturing with novel regulation of AAV expression cassettes and process optimizations for better infectivity and higher full-capsid ratio.
Opportunities
Growing global demand for gene therapy CDMO services, expansion into international markets through its U.S.
office, and leveraging proprietary One-Bac 4.0 technology for competitive advantage in AAV manufacturing.
Risk Factors
Intense competition from established global CDMOs, dependence on partner pipeline success, regulatory challenges in multiple jurisdictions, and capital intensity of maintaining and expanding manufacturing facilities.
Competitive Landscape
Competes with global CDMOs like Lonza, Catalent, and Charles River Laboratories, as well as Chinese CDMOs like Wuxi Biologics and Pharmaron, differentiated by specialized focus on viral vectors and proprietary One-Bac 4.0 AAV manufacturing technology.